Delivery Order SPE2DB22D2211-SPE2DB25FSDGE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,072.56 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This competitive, non-set-aside contract award was executed on August 7, 2025, with an ultimate completion date of August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract operates under a firm fixed-price delivery order structure,...
- The Defense Logistics Agency awarded a delivery order valued at $1,450.14 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic medication. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement with an ultimate completion date of August 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency valued at $2,491.58 for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic medication. The contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, and represents a firm fixed-price procurement with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,538.10 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This non-set-aside, competitively awarded delivery order was issued on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award utilizes firm fixed price pricing and represents a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 4565366325 - Clindamycin Phosphate 1% Foam, 50 gm. The order has a firm fixed-price of $2,838.07 and the period of performance runs through August 7, 2024. As a major pharmaceutical distributor, AmerisourceBergen provides a wide range of prescription medications, over-the-counter drugs, and medical supplies to support various government agencies and healthcare programs,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,425.95 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam in 50-gram units. This contract, awarded on August 11, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award, indicating it was competitively procured through...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Clindamycin Phosphate 1% Foam, 100 grams, with a ceiling value of $1,217.44 and a performance period through June 10, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin Phosphate 1% Foam in 50 gram units. The contract has a ceiling value of $1,671.89 and a completion date of July 9, 2025. It is a Firm Fixed Price Delivery Order contract, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
- This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4560408677 - Clindamycin Phosphate 1% Foam 50GM, with a ceiling value of $2,433.39 and a completion date of March 29, 2023. This Delivery Order is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4558478384 - Clindamycin Phosphate 1% Foam, 100 gm, with a ceiling value of $1,339.74 and a completion date of September 16, 2022. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026, which serves as...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDGEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,323.00 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM on August 20, 2025, with completion expected by August 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates significant capacity to fulfill diverse medical procurement requirements across multiple therapeutic domains, positioning the company as a critical vendor for Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 8/20/25 |